Restructured Melinta now wants to buy fellow antibiotic maker Tetraphase; TA Associates mulls $500M deal for a stake in CDMO
→ Yet another buyer has emerged in what is shaping up to be a bidding war for Tetraphase and its marketed antibiotic. Melinta …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
